Inventor · disambiguated record
David S. Millan
Also filed as: MILLAN DAVID · MILLAN DAVID J · MILLAN DAVID S · MILLAN DAVID SIMON
62 granted patents·15 pending applications·679 citations·filing 2003–2023
99Inventor score
Files withFORMA THERAPEUTICS INC46FOGHORN THERAPEUTICS INC7VALO HEALTH INC5VALO EARLY DISCOVERY INC4BEAUDOIN SERGE2
Top patents by PatentIndex Score
77 records- 0199US10829461B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO EARLY DISCOVERY INC·Filed 2019·Granted Nov 10, 2020·15 cites·12 claims
- 0299US10829462B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO EARLY DISCOVERY INC·Filed 2019·Granted Nov 10, 2020·15 cites·17 claims
- 0399US10377726B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Aug 13, 2019·22 cites·10 claims
- 0499US10112915B23-aryl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Oct 30, 2018·41 cites·31 claims
- 0598US11279681B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO HEALTH INC·Filed 2020·Granted Mar 22, 2022·6 cites·20 claims
- 0698US10822316B23-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO EARLY DISCOVERY INC·Filed 2019·Granted Nov 3, 2020·10 cites·15 claims
- 0798US10494354B23-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 3, 2019·17 cites·17 claims
- 0898US10494353B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 3, 2019·17 cites·12 claims
- 0998US10472337B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Nov 12, 2019·17 cites·12 claims
- 1098US10428031B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Oct 1, 2019·15 cites·20 claims
- 1198US10421731B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Sep 24, 2019·15 cites·19 claims
- 1298US10421732B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Sep 24, 2019·16 cites·13 claims
- 1398US10414738B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Sep 17, 2019·16 cites·20 claims
- 1498US10239845B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Mar 26, 2019·25 cites·42 claims
- 1598US10214501B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Feb 26, 2019·20 cites·38 claims
- 1698US10214500B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Feb 26, 2019·20 cites·35 claims
- 1798US9630922B23-spiro-7-hydroxamic acid tetralins as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Apr 25, 2017·49 cites·33 claims
- 1897US10988450B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO EARLY DISCOVERY INC·Filed 2019·Granted Apr 27, 2021·6 cites·14 claims
- 1997US10513501B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 24, 2019·11 cites·20 claims
- 2097US10494352B23-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 3, 2019·12 cites·20 claims
- 2197US10494351B23-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 3, 2019·12 cites·20 claims
- 2297US10464910B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Nov 5, 2019·12 cites·15 claims
- 2397US10464909B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Nov 5, 2019·12 cites·17 claims
- 2497US10457652B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Oct 29, 2019·12 cites·18 claims
- 2597US10450283B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Oct 22, 2019·14 cites·16 claims
- 2697US10450284B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Oct 22, 2019·14 cites·13 claims
- 2797US10442776B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Oct 15, 2019·15 cites·18 claims
- 2897US10336722B2Tetrahydroquinoline compositions as BET bromodomain inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Jul 2, 2019·22 cites·47 claims
- 2997US9422281B2Benzopiperazine compositions as BET bromodomain inhibitorsFORMA THERAPEUTICS INC·Filed 2014·Granted Aug 23, 2016·25 cites·35 claims
- 3096US11111229B2Tetrahydroquinoline compositions as BET bromodomain inhibitorsFORMA THERAPEUTICS INC·Filed 2020·Granted Sep 7, 2021·4 cites·22 claims
- 3196US10377769B2Benzopiperazine compositions as BET bromodomain inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Aug 13, 2019·10 cites·28 claims
- 3296US9388161B2Tetrahydroquinoline compositions as BET bromodomain inhibitorsFORMA THERAPEUTICS INC·Filed 2014·Granted Jul 12, 2016·34 cites·44 claims
- 3395US11497752B2Compounds and uses thereofFOGHORN THERAPEUTICS INC·Filed 2019·Granted Nov 15, 2022·7 cites·6 claims
- 3494US10611750B2Tetrahydroquinoline compositions as bet bromodomain inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Apr 7, 2020·7 cites·38 claims
- 3594US10479772B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Nov 19, 2019·6 cites·13 claims
- 3694US10472342B2Compounds and compositions for inhibition of FASNFORMA THERAPEUTICS INC·Filed 2019·Granted Nov 12, 2019·4 cites·25 claims
- 3793US8153814B2Sulfonamide derivativesBEAUDOIN SERGE·Filed 2010·Granted Apr 10, 2012·36 cites·6 claims
- 3892US12383560B2Compounds and uses thereofFOGHORN THERAPEUTICS INC·Filed 2022·Granted Aug 12, 2025·1 cites·10 claims
- 3992US11891365B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO HEALTH INC·Filed 2021·Granted Feb 6, 2024·1 cites·23 claims
- 4092US11773085B2Methods and compounds for treating disordersFOGHORN THERAPEUTICS INC·Filed 2020·Granted Oct 3, 2023·10 cites·4 claims
- 4190US10457655B2Compounds and compositions for inhibition of FASNFORMA THERAPEUTICS INC·Filed 2017·Granted Oct 29, 2019·3 cites·46 claims
- 4290US10399951B2Compounds and compositions for inhibition of FASNFORMA THERAPEUTICS INC·Filed 2018·Granted Sep 3, 2019·5 cites·27 claims
- 4389US11274084B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO HEALTH INC·Filed 2020·Granted Mar 15, 2022·1 cites·18 claims
- 4487US10703764B2Benzopiperazine compositions as BET bromodomain inhibitorsFORMA THERAPEUTICS INC·Filed 2019·Granted Jul 7, 2020·2 cites·19 claims
- 4587US10450286B2Compounds and compositions for inhibition of FASNFORMA THERAPEUTICS INC·Filed 2019·Granted Oct 22, 2019·3 cites·27 claims
- 4687US7511057B2Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitorsPFIZER·Filed 2005·Granted Mar 31, 2009·11 cites·22 claims
- 4786US10995078B2Compounds and compositions for inhibition of FASNFORMA THERAPEUTICS INC·Filed 2020·Granted May 4, 2021·1 cites·2 claims
- 4885US12264137B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO HEALTH INC·Filed 2022·Granted Apr 1, 2025·0 cites·17 claims
- 4985US10501424B23-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 10, 2019·1 cites·17 claims
- 5081US8541588B2Sulfonamide derivativesBEAUDOIN SERGE·Filed 2012·Granted Sep 24, 2013·6 cites·18 claims
Showing the top 50 of 77 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →